First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases

International Journal of Cancer

Volumn 127, Issue 6, 2010, Pages 1475-1485

  Rasheed, Suhail Ahmed Kabeer ^a   Efferth, Thomas ^b   Asangani, Irfan Ahmed ^a   Allgayer, Heike ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Artesunate; Metastasis; Non small cell lung cancer

Indexed keywords

ARTESUNATE; GELATINASE A; LUCIFERASE; MATRILYSIN; MESSENGER RNA; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CHICK EMBRYO; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77955641219     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25315     Document Type: Article

References (49)

1. Coello MC, Luketich JD, Litle VR, Godfrey TE. Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer 2004;5:214-25.
2. Engers R, Gabbert HE. Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol 2000;126:682-92.
3. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 1998;13:893-906. (Pubitemid 28506055)
4. Morita S, Sato A, Hayakawa H, Ihara H, Urano T, Takada Y, Takada A. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization. Int J Cancer 1998;78:286-92. (Pubitemid 28445362)
5. Montuori N, Mattiello A, Mancini A, Taglialatela P, Caputi M, Rossi G, Ragno P. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma. Int J Cancer 2003;105:353-60. (Pubitemid 36570048)
6. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, Chu SC. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354:91-9.
7. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200: 448-64. (Pubitemid 36818245)
8. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66. (Pubitemid 34309470)
9. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
10. Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, Kadota K, Urushihara M, Huang CL. Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 2007;58:384-91. (Pubitemid 350051513)
11. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, Lakka S. Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 2006;5:2289-99. (Pubitemid 44530466)
12. Yue W, Sun Q, Landreneau R, Wu C, Siegfried JM, Yu J, Zhang L. Fibulin-5 suppresses lung cancer invasion by inhibiting matrix metalloproteinase-7 expression. Cancer Res 2009;69:6339-46.
13. Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic - thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995;55:753-60.
14. Price RN. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 2000;9:1815-27.
15. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The antimalarial artesunate is also active against cancer. Int J Oncol 2001;18:767-73.
16. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH, Efferth T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One 2007;2:e798.
17. Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, Efferth T. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 2004;68:2359-66. (Pubitemid 39535108)
18. Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 2003;48:231-6. (Pubitemid 36818928)
19. Chen HH, Zhou HJ, Wu GD, Lou XE. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 2004;71:1-9.
20. Wartenberg M, Wolf S, Budde P, Grunheck F, Acker H, Hescheler J, Wartenberg G, Sauer H. The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cellderived embryoid bodies. Lab Invest 2003; 83:1647-55. (Pubitemid 37421105)
21. Huan-Huan C, Li-Li Y, Shang-Bin L. Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. Cancer Lett 2004;211:163-73. (Pubitemid 38824630)
22. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, Hafer R, Stamminger T, Oesch F, Kaina B, Marschall M. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 2004;37: 998-1009. (Pubitemid 39164582)
23. Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008; 68:4347-51.
24. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008;269:199-225.
25. Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H. Tumor suppressor Pdcd4 inhibits invasion/ intravasation and regulates urokinase receptor (u-PAR) gene expression via Sptranscription factors. Oncogene 2007;26: 4550-62. (Pubitemid 47039134)
26. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) posttranscriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27:2128-36. (Pubitemid 351485639)
27. Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res 2009;69: 2461-70.
28. Fong YC, Hsu SF, Wu CL, Li TM, Kao ST, Tsai FJ, Chen WC, Liu SC, Wu CM, Tang CH. Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer 2009;64:13-21.
29. Paul R, Ewing CM, Robinson JC, Marshall FF, Johnson KR, Wheelock MJ, Isaacs WB. Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma. Cancer Res 1997;57:2741-8. (Pubitemid 27283788)
30. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 2001;3: 650-7. (Pubitemid 32624421)
31. Wong SY, Haack H, Crowley D, Barry M, Bronson RT, Hynes RO. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res 2005;65:9789-98. (Pubitemid 41541456)
32. Nasi S, Ciarapica R, Jucker R, Rosati J, Soucek L. Making decisions through Myc. FEBS Lett 2001;490:153-62.
33. Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L, Rhys-Evans P, O-charoenrat P, Eccles S. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 2007;67: 7907-16. (Pubitemid 47281387)
34. Luo Y, Liang F, Zhang ZY. PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry 2009; 48:1838-46.
35. Wroblewski LE, Noble PJ, Pagliocca A, Pritchard DM, Hart CA, Campbell F, Dodson AR, Dockray GJ, Varro A. Stimulation of MMP-7 (matrilysin) by Helicobacter pylori in human gastric epithelial cells: role in epithelial cell migration. J Cell Sci 2003;116:3017-26. (Pubitemid 36926990)
36. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999;56: 104-32.
37. Arkan MC, Leonarduzzi G, Biasi F, Basaga H, Poli G. Physiological amounts of ascorbate potentiate phorbol ester-induced nuclear-binding of AP-1 transcription factor in cells of macrophagic lineage. Free Radic Biol Med 2001;31:374-82. (Pubitemid 32675343)
38. Suzuki YJ, Mizuno M, Packer L. Transient overexpression of catalase does not inhibit TNF- or PMA-induced NF-kappa B activation. Biochem Biophys Res Commun 1995;210:537-41.
39. Efferth T, Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem Pharmacol 2004; 68:3-10. (Pubitemid 38746536)
40. Harvey SR, Lawrence DD, Madeja JM, Abbey SJ, Markus G. Secretion of plasminogen activators by human colorectal and gastric tumor explants. Clin Exp Metastasis 1988;6:431-50.
41. Yu HR, Schultz RM. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 1990;50:7623-33.
42. Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 1995;63:840-5.
43. Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997;57:3585-93. (Pubitemid 27355511)
44. Alonso DF, Farias EF, Ladeda V, Davel L, Puricelli L, Bal de Kier Joffe E. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 1996;40:209-23.
45. Iniesta P, Moran A, De Juan C, Gomez A, Hernando F, Garcia-Aranda C, Frias C, Diaz-Lopez A, Rodriguez-Jimenez FJ, Balibrea JL, Benito M. Biological and clinical significance of MMP-2. MMP-9, TIMP-1 and. TIMP-2 in non-small cell lung cancer. Oncol Rep 2007;17: 217-23.
46. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H, Allgayer H. Urokinase receptor MMP-1 and MMP- 9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 2009;125: 894-901.
47. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist Updat 2005;8:85-97.
48. Reungpatthanaphong P, Mankhetkorn S. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/ adr resistant cell lines. Biol Pharm Bull 2002;25:1555-61. (Pubitemid 39663669)
49. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G. Artesunate in the treatment of metastatic uveal melanoma - first experiences. Oncol Rep 2005;14:1599-603.